Delving into the Latest Updates on Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute) with Synapse

Overview

Basic Info

Drug Type

TIL therapy

Synonyms

CD40L TIL(H. Lee Moffitt Cancer Center and Research Institute)

Target

CD40L

Mechanism

CD40L stimulants(CD40 ligand stimulants), Immunologic cytotoxicity, T lymphocyte replacements

Therapeutic Areas

NeoplasmsRespiratory Diseases

Active Indication

metastatic non-small cell lung cancerRecurrent Non-Small Cell Lung Cancer

Inactive Indication-

Originator Organization

H. Lee Moffitt Cancer Center & Research Institute, Inc.

Active Organization

H. Lee Moffitt Cancer Center & Research Institute, Inc.

Inactive Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

Investigators plan to study the safety, side effects, and benefits of tumor-infiltrating lymphocytes (TILs) when they are given with the drug nivolumab. Nivolumab is a type of immunotherapy - a drug that is used to boost the ability of the immune system to fight cancer, infection, and other diseases.

Start Date11 Oct 2017

Sponsor / Collaborator

H. Lee Moffitt Cancer Center & Research Institute, Inc.

[+4]

100 Clinical Results associated with Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute)

Login to view more data

100 Translational Medicine associated with Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute)

Login to view more data

100 Patents (Medical) associated with Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute)

Login to view more data

100 Deals associated with Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
metastatic non-small cell lung cancer	Phase 2	US	H. Lee Moffitt Cancer Center & Research Institute, Inc.	10 Mar 2023
Recurrent Non-Small Cell Lung Cancer	Phase 2	US	H. Lee Moffitt Cancer Center & Research Institute, Inc.	10 Mar 2023

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESMO2024	Not Applicable	Unresectable Melanoma	102	Tumor Infiltrating Lymphocytes (TIL)	dsyikhnqvi(htvloaswxk) = ICI-related toxicity was identified in 22 patients (24%), and among those 6 patients (27%) had a recurrence of a toxicity seen with pre-TIL ICI sftzxxwnag (agfikiunjr ) View more	Negative	14 Sep 2024
ESMO2024	Not Applicable	Unresectable Melanoma	102	Immune Checkpoint Inhibitor (ICI) Rechallenge		Negative	14 Sep 2024
SITC2022	Not Applicable	Non-Small Cell Lung Cancer PD-1+ \| IFN-Î³	103	tumor-infiltrating lymphocytes (Initial Expansion (IE) TILs)	qpwgbpwuft(trlxlurosk) = ovqgskhdrv prnvqpuotl (fnkyskxfvz, 0.02 - 30.8) View more	Positive	07 Nov 2022
SITC2022	Not Applicable	Non-Small Cell Lung Cancer PD-1+ \| IFN-Î³	103	tumor-infiltrating lymphocytes (Rapid Expansion (REP) TILs)	pnxjumhyth(dbsuzuczyj) = akbhvriawo dqgvihhpgb (endbvyihdu ) View more	Positive	07 Nov 2022
SITC2016	Phase 2	Melanoma	-	TIL therapy	aznyvlucfv(hxljrvizqk) = aujodjrzfy fhdywzfyrk (rbqowwcxrc )	Positive	16 Nov 2016
SITC2014	Phase 1	Pancreatic Cancer mesothelin \| survivin \| NY-ESO-1	16	IL-2/IL-15/IL-21-expanded TIL	ygjhikguws(txwgftudpk) = 1/16 TIL cultures exhibited exclusively CD4+ TIL with a CD45RA-CCR7+ phenotype etdhbuzwbp (kkjfaxblzd ) View more	-	06 Nov 2014
ASCO2014	Phase 2	Metastatic melanoma	56	Tumor-infiltrating lymphocytes (TIL)	isebiclgou(nflmyfopry) = kxmzzzonhi aibjwbnfhq (pcohbdegwv )	Positive	20 May 2014